Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- Another strategy to maintain suppression but minimize toxicity and cost is to switch to dual therapy with a ritonavir-boosted PI plus a single NRTI
- The use of dual atazanavir plus ritonavir plus lamivudine therapy for maintenance of viral suppression has been evaluated in several trials
- SALT: dual boosted atazanavir plus lamivudine was noninferior to triple therapy of boosted atazanavir plus 2 NRTIs for maintenance of virologic suppression through 48 weeks[Perez-Molina 2015]
- SALT: dual boosted atazanavir plus lamivudine was noninferior to triple therapy of boosted atazanavir plus 2 NRTIs for maintenance of virologic suppression through 48 weeks[Perez-Molina 2015]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Switch Strategies